DK1648874T3 - Piperazinderivater samt deres anvendelse som terapeutisk aktive stoffer - Google Patents

Piperazinderivater samt deres anvendelse som terapeutisk aktive stoffer

Info

Publication number: DK1648874T3
Authority: DK; Denmark
Prior art keywords: well; active substances; therapeutically active; piperazine derivatives; piperazine
Prior art date: 2003-07-30

Application number

DK04779562.0T

Other languages

English (en)

Inventor

Melwyn Abreo

Mikhail Chafeev

Sultan Chowdhury

Jian-Min Fu

Heinz W Gschwend

Mark W Holladay

Rajender Kamboj

Wenbao Li

Shifeng Liu

Vandna Raina

Sengen Sun

Serguei Sviridov

Chi Tu

Zaihui Zhang

Duanjie Hou

Michael D Winther

Nagasree Chakka

Vishnumurthy Kodumuru

Shaoyi Sun

Original Assignee

Xenon Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-30

Filing date

2004-07-29

Publication date

2012-01-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34120234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1648874(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-07-29 Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc

2012-01-23 Application granted granted Critical

2012-01-23 Publication of DK1648874T3 publication Critical patent/DK1648874T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Gastroenterology & Hepatology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

DK04779562.0T 2003-07-30 2004-07-29 Piperazinderivater samt deres anvendelse som terapeutisk aktive stoffer DK1648874T3 (da)

Applications Claiming Priority (12)

Application Number	Priority Date	Filing Date	Title
US49109503P	2003-07-30	2003-07-30
US54693404P	2004-02-23	2004-02-23
US54681504P	2004-02-23	2004-02-23
US54682004P	2004-02-23	2004-02-23
US54678604P	2004-02-23	2004-02-23
US54689804P	2004-02-23	2004-02-23
US55340404P	2004-03-16	2004-03-16
US55344604P	2004-03-16	2004-03-16
US55349104P	2004-03-16	2004-03-16
US55340304P	2004-03-16	2004-03-16
US55341604P	2004-03-16	2004-03-16
PCT/US2004/024548 WO2005011655A2 (en)	2003-07-30	2004-07-29	Pyridazine derivatives and their use as therapeutic agents

Publications (1)

Publication Number	Publication Date
DK1648874T3 true DK1648874T3 (da)	2012-01-23

Family

ID=34120234

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK04779562.0T DK1648874T3 (da)	2003-07-30	2004-07-29	Piperazinderivater samt deres anvendelse som terapeutisk aktive stoffer

Country Status (23)

Country	Link
US (1)	US7335658B2 (da)
EP (3)	EP2316827B1 (da)
JP (1)	JP4808616B2 (da)
KR (1)	KR100934554B1 (da)
AR (1)	AR047557A1 (da)
AT (1)	ATE527242T1 (da)
AU (2)	AU2004261252C1 (da)
CA (1)	CA2533899C (da)
CY (1)	CY1112178T1 (da)
DK (1)	DK1648874T3 (da)
EC (1)	ECSP066313A (da)
ES (2)	ES2568769T3 (da)
HK (1)	HK1226399A1 (da)
HR (1)	HRP20110974T1 (da)
IL (1)	IL173395A (da)
MA (1)	MA28011A1 (da)
NO (1)	NO332822B1 (da)
NZ (1)	NZ545265A (da)
PL (1)	PL1648874T3 (da)
PT (1)	PT1648874E (da)
TN (1)	TNSN06034A1 (da)
TW (2)	TWI345974B (da)
WO (1)	WO2005011655A2 (da)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040226056A1 (en) *	1998-12-22	2004-11-11	Myriad Genetics, Incorporated	Compositions and methods for treating neurological disorders and diseases
US20050119251A1 (en) *	2001-12-21	2005-06-02	Jian-Min Fu	Nicotinamide derivatives and their use as therapeutic agents
US7390813B1 (en) *	2001-12-21	2008-06-24	Xenon Pharmaceuticals Inc.	Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
TWI345974B (en)	2003-07-30	2011-08-01	Xenon Pharmaceuticals Inc	Pyridazine derivatives and their use in the inhibition of stearoyl-coa desaturase
US7754711B2 (en) *	2003-07-30	2010-07-13	Xenon Pharmaceuticals Inc.	Pyridazine derivatives and their use as therapeutic agents
ES2386353T3 (es) *	2003-07-30	2012-08-17	Xenon Pharmaceuticals Inc.	Derivados de piridazina y su uso como agentes terapéuticos
US7759348B2 (en)	2003-07-30	2010-07-20	Xenon Pharmaceuticals Inc.	Pyridazine derivatives and their use as therapeutic agents
CN101693697A (zh) *	2003-07-30	2010-04-14	泽农医药公司	哌嗪衍生物和它们作为治疗剂的用途
EP1737414A2 (en) *	2004-01-23	2007-01-03	Amgen Inc.	Vanilloid receptor ligands and their use in treatments of inflammatory and neuropatic pain
US7547698B2 (en) *	2004-09-20	2009-06-16	Xenon Pharmaceuticals Inc.	Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coadesaturase (SCD)
AR051093A1 (es)	2004-09-20	2006-12-20	Xenon Pharmaceuticals Inc	Derivados heterociclicos y su uso como inhibidores de estearoil-coa desaturasa
EP1830837B1 (en)	2004-09-20	2013-09-04	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
JP5149009B2 (ja) *	2004-09-20	2013-02-20	ゼノン・ファーマシューティカルズ・インコーポレイテッド	ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリダジン誘導体
AR051090A1 (es) *	2004-09-20	2006-12-20	Xenon Pharmaceuticals Inc	Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
MX2007003332A (es)	2004-09-20	2007-06-05	Xenon Pharmaceuticals Inc	Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
CN101090724A (zh) *	2004-09-20	2007-12-19	泽农医药公司	用于抑制人硬脂酰CoA去饱和酶的吡啶衍生物
MX2007003325A (es) *	2004-09-20	2007-06-05	Xenon Pharmaceuticals Inc	Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa.
AU2005286728A1 (en) *	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
GT200600046A (es) *	2005-02-09	2006-09-25		Terapia de combinacion
WO2007044085A2 (en) *	2005-05-19	2007-04-19	Xenon Pharmaceuticals Inc.	Heteroaryl compounds and their uses as therapeutic agents
WO2006125180A1 (en) *	2005-05-19	2006-11-23	Xenon Pharmaceuticals Inc.	Piperazine derivatives and their uses as therapeutic agents
WO2006125179A1 (en) *	2005-05-19	2006-11-23	Xenon Pharmaceuticals Inc.	Tricyclic compounds and their uses as therapeutic agents
EP2029138A1 (en)	2005-06-03	2009-03-04	Xenon Pharmaceuticals Inc.	Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
WO2007005763A2 (en) *	2005-07-01	2007-01-11	Novartis Ag	Combination of a renin inhibitor and an insulin secretion enhancer or an insulin sensitizer
JO2769B1 (en)	2005-10-26	2014-03-15	جانسين فارماسوتيكا ان. في	Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
WO2007071023A1 (en) *	2005-12-20	2007-06-28	Merck Frosst Canada Ltd.	Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US7989461B2 (en) *	2005-12-23	2011-08-02	Amgen Inc.	Substituted quinazolinamine compounds for the treatment of cancer
WO2007136746A2 (en) *	2006-05-19	2007-11-29	Xenon Pharmaceuticals Inc.	Macrocyclic compounds and their uses as stearoyl-coa desaturase
PT2029572E (pt)	2006-06-05	2011-02-09	Novartis Ag	Compostos orgânicos
CN101506203B (zh)	2006-08-24	2013-10-16	诺瓦提斯公司	治疗代谢病、心血管病和其他病症的作为硬脂酰辅酶a脱饱和酶(scd)抑制剂的2-(吡嗪-2-基)-噻唑和2-(1h-吡唑-3-基)-噻唑衍生物及相关化合物
US8246433B2 (en) *	2006-08-25	2012-08-21	Alma Mater Sports, Llc	Team based fantasy sport contest
WO2008056687A1 (en) *	2006-11-09	2008-05-15	Daiichi Sankyo Company, Limited	Novel spiropiperidine derivative
AU2007323193A1 (en) *	2006-11-20	2008-05-29	Glenmark Pharmaceuticals S.A.	Acetylene derivatives as Stearoyl CoA Desaturase inhibitors
US8575167B2 (en)	2007-02-06	2013-11-05	Takeda Pharmaceutical Company Limited	Spiro compounds having stearoyl-CoA desaturase action
JO2849B1 (en)	2007-02-13	2015-03-15	جانسين فارماسوتيكا ان. في	Dopamine 2 receptor antagonists are rapidly hydrolyzed
JP2010520162A (ja) *	2007-02-28	2010-06-10	スミスクラインビーチャムコーポレーション	ステアロイル−ＣｏＡデサチュラーゼ阻害剤であるチアジアゾール誘導体
KR20100016620A (ko) *	2007-04-23	2010-02-12	얀센 파마슈티카 엔.브이.	속해리성 도파민 2 수용체 길항제로서의 4-알콕시피리다진 유도체
MX2009011416A (es)	2007-04-23	2009-11-05	Janssen Pharmaceutica Nv	Tia(di)azoles como antagonistas del receptor de dopamina 2 de disociacion rapida.
ES2571533T3 (es) *	2007-04-27	2016-05-25	Purdue Pharma Lp	Antagonistas de TRPV1 y usos de los mismos
IN2009KN04568A (da)	2007-06-01	2015-08-28	Univ Princeton
WO2008157844A1 (en)	2007-06-21	2008-12-24	Forest Laboratories Holdings Limited	Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase
ES2352098T3 (es)	2007-08-08	2011-02-15	Graceway Pharmaceuticals, Llc	Derivado de fenoxi-pirrolidina y su uso y composiciones.
WO2009037542A2 (en)	2007-09-20	2009-03-26	Glenmark Pharmaceuticals, S.A.	Spirocyclic compounds as stearoyl coa desaturase inhibitors
BRPI0817211A2 (pt)	2007-09-20	2017-05-16	Irm Llc	composto composições como moduladores da atividade de gpr119
MX2010006108A (es) *	2007-12-11	2010-06-25	Hoffmann La Roche	Inhibidores de estearoil-coa-desaturasa.
KR101609218B1 (ko) *	2008-07-31	2016-04-05	얀센 파마슈티카 엔.브이.	속해리성 도파민 2 수용체 길항제로서의 피페라진-1-일-트리플루오로메틸-치환된-피리딘
AU2010215035B2 (en)	2009-02-17	2014-06-12	Merck Canada Inc.	Novel spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
WO2011011872A1 (en)	2009-07-28	2011-02-03	Merck Frosst Canada Ltd.	Novel spiro compounds useful as inhibitors of stearoyl-coenzyme a delta-9 desaturase
WO2011014520A2 (en)	2009-07-29	2011-02-03	Irm Llc	Compounds and compositions as modulators of gpr119 activity
WO2011030312A1 (en)	2009-09-10	2011-03-17	Institut National De La Sante Et De La Recherche Medicale (Inserm)	NOVEL INHIBITORS OF STEAROYL-CoA-DESATURASE-1 AND THEIR USES
CN102686579A (zh)	2009-10-09	2012-09-19	Irm责任有限公司	作为gpr119活性调节剂的化合物和组合物
US8394858B2 (en)	2009-12-03	2013-03-12	Novartis Ag	Cyclohexane derivatives and uses thereof
US8697739B2 (en)	2010-07-29	2014-04-15	Novartis Ag	Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
ES2620528T3 (es)	2011-06-22	2017-06-28	Purdue Pharma Lp	Antagonistas de TRPV1 que incluyen un sustituyente dihidroxi y usos de los mismos
CA2850836A1 (en)	2011-10-15	2013-04-18	Genentech, Inc.	Methods of using scd1 antagonists
AU2013241854B2 (en) *	2012-03-28	2017-11-02	Intervet International B.V.	Heteroaryl compounds with cyclic bridging unit for use in the treatment helminth infection
EP2852387A2 (en)	2012-05-22	2015-04-01	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.	Selective inhibitors of undifferentiated cells
WO2014052619A1 (en)	2012-09-27	2014-04-03	Irm Llc	Piperidine derivatives and compositions as modulators of gpr119 activity
PH12018500586B1 (en)	2015-09-16	2023-08-11	Organovo Inc	Farnesoid x receptor agonists and uses thereof
US11970486B2 (en)	2016-10-24	2024-04-30	Janssen Pharmaceutica Nv	Compounds and uses thereof
AU2018205275B2 (en)	2017-01-06	2024-05-02	Janssen Pharmaceutica Nv	Methods for the treatment of neurological disorders
CN110637015B (zh)	2017-03-15	2024-04-02	奥加诺沃公司	法尼醇x受体激动剂及其用途
JP7174709B2 (ja)	2017-03-15	2022-11-17	メタクリン，インク．	ファルネソイドｘ受容体アゴニストおよびその使用
US11873298B2 (en)	2017-10-24	2024-01-16	Janssen Pharmaceutica Nv	Compounds and uses thereof
AU2019238326B2 (en)	2018-03-23	2025-03-06	Janssen Pharmaceutica Nv	Compounds and uses thereof
EP3778577B1 (en) *	2018-05-09	2023-08-30	Lg Chem, Ltd.	Novel compound exhibiting enteropeptidase inhibitory activity
FI3852748T3 (fi)	2018-09-18	2025-10-22	Lilly Co Eli	Farnesoid x -reseptoriagonisteja ja niiden käyttötapoja
KR20220007845A (ko)	2019-01-24	2022-01-19	유마니티 테라퓨틱스, 인크.	화합물 및 이의 용도
EA202192047A1 (ru)	2019-11-13	2021-12-08	Юманити Терапьютикс, Инк.	Соединения и их применение
WO2021188695A1 (en)	2020-03-18	2021-09-23	Metacrine, Inc.	Formulations of a farnesoid x receptor agonist

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US667452A (en) *	1900-09-08	1901-02-05	John A Hendrickson	Computing attachment for pumps.
US2985657A (en)	1959-10-12	1961-05-23	Paul A J Janssen	1-(aroylalkyl)-4-heterocyclylpiperazines
DE2341925A1 (de)	1973-08-20	1975-03-06	Thomae Gmbh Dr K	Neue pyrimidinderivate und verfahren zu ihrer herstellung
AT340933B (de)	1973-08-20	1978-01-10	Thomae Gmbh Dr K	Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
US5001125A (en)	1984-03-26	1991-03-19	Janssen Pharmaceutica N.V.	Anti-virally active pyridazinamines
ES8802151A1 (es)	1985-07-31	1988-04-01	Janssen Pharmaceutica Nv	Un procedimiento para la preparacion de nuevos piridazinaminas.
US4996318A (en)	1987-04-03	1991-02-26	The Upjohn Company	Amino-9,10-secosteroids useful for treating head injury, spinal cord trauma or stroke
CA1338012C (en)	1987-04-27	1996-01-30	John Michael Mccall	Pharmaceutically active amines
MY104343A (en)	1987-11-23	1994-03-31	Janssen Pharmaceutica Nv	Novel pyridizinamine deravatives
US4994456A (en)	1989-03-01	1991-02-19	Nisshin Flour Milling Co., Ltd.	Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same
IL96891A0 (en)	1990-01-17	1992-03-29	Merck Sharp & Dohme	Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
US5166147A (en)	1990-07-09	1992-11-24	The Du Pont Merck Pharmaceutical Company	4-heteroaryl-and 4-aryl-1,4-dihydropyridine, derivatives with calcium agonist and alpha1 -antagonist activity
GB9019143D0 (en) *	1990-09-01	1990-10-17	Bp Chem Int Ltd	Thixotropic compositions
EP0520292A1 (de)	1991-06-19	1992-12-30	Hoechst Aktiengesellschaft	Chirale Azetidinon-Derivate und ihre Verwendung als Dotierstoffe in Flüssigkristallmischungen
DE4302051A1 (de)	1993-01-26	1994-07-28	Thomae Gmbh Dr K	5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
ES2162235T3 (es) *	1996-01-15	2001-12-16	Janssen Pharmaceutica Nv	Piridazinaminas inhibidoras de la angiogenesis.
DE19614204A1 (de) *	1996-04-10	1997-10-16	Thomae Gmbh Dr K	Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
JPH107572A (ja)	1996-06-17	1998-01-13	Sumitomo Pharmaceut Co Ltd	腫瘍壊死因子産生阻害剤
WO1999000386A1 (en)	1997-06-27	1999-01-07	Resolution Pharmaceuticals Inc.	Dopamine d4 receptor ligands
WO1999047507A2 (en)	1998-03-19	1999-09-23	Pharmacia & Upjohn Company	1,3,4-thiadiazoles useful for the treatment of cmv infections
WO2000023450A1 (en)	1998-10-21	2000-04-27	Takeda Chemical Industries, Ltd.	Fused pyridazine derivatives, process for the preparation of the same and uses thereof
AU1455500A (en)	1998-10-29	2000-05-22	Trega Biosciences, Inc.	Oxadiazole, thiadiazole and triazole derivatives and combinatorial libraries thereof
WO2000044743A1 (en)	1999-01-28	2000-08-03	Nippon Shinyaku Co., Ltd.	Amide derivatives and drug compositions
DE60006213T2 (de)	1999-01-29	2004-07-29	Abbott Laboratories, Abbott Park	Diazabicyloderivate als nikotin-acetylcholin-rezeptorliganden
ES2226622T3 (es)	1999-02-24	2005-04-01	F. Hoffmann-La Roche Ag	Derivados de 4-fenil piridina y su empleo como antagonistas del receptor nk-1.
CA2369103A1 (en)	1999-04-09	2000-10-19	Meiji Seika Kaisha, Ltd.	Nitrogen-containing heterocyclic compounds and benamide compounds and drugs containing the same
JP3637961B2 (ja) *	1999-09-16	2005-04-13	田辺製薬株式会社	芳香族含窒素六員環化合物
US6677452B1 (en)	1999-09-30	2004-01-13	Lion Bioscience Ag	Pyridine carboxamide or sulfonamide derivatives and combinatorial libraries thereof
WO2001043746A1 (en)	1999-12-14	2001-06-21	Nippon Shinyaku Co., Ltd.	Medicinal composition
ATE475718T1 (de) *	2000-02-24	2010-08-15	Xenon Pharmaceuticals Inc	Stearoyl-coa-desaturase zur identifizierung von triglyceridreduktionstherapeutika
BR0109188A (pt)	2000-03-15	2003-03-18	Warner Lambert Co	Diarilaminas 5-amida substituìdas como inibidores de mex
US20020045613A1 (en)	2000-04-27	2002-04-18	Heinz Pauls	1-aroyl-piperidinyl benzamidines
GB0013383D0 (en)	2000-06-01	2000-07-26	Glaxo Group Ltd	Therapeutic benzamide derivatives
DE60130771T2 (de) *	2000-07-27	2008-07-17	Eli Lilly And Co., Indianapolis	Substituierte heterocyclische amide
CA2430987A1 (en)	2000-09-26	2002-04-04	Xenon Genetics, Inc.	Methods and compositions employing a novel stearoyl-coa desaturase-hscd5
DE10060412A1 (de)	2000-12-05	2002-06-06	Bayer Ag	DELTA1-Pyrroline
US20020169166A1 (en)	2001-03-09	2002-11-14	Cowart Marlon D.	Benzimidazoles that are useful in treating sexual dysfunction
FR2823209B1 (fr)	2001-04-04	2003-12-12	Fournier Lab Sa	Nouvelles thiohydantoines et leur utilisation en therapeutique
BR0209932A (pt) *	2001-05-22	2004-10-13	Neurogen Corp	Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, preparação farmacêutica embalada, métodos para modular ligação de mch a um receptor de mch e de mvc, para alterar a atividade de transdução de sinal de um receptor de mch em uma célula, para tratar uma doença ou distúrbio associado com a ativação de receptor de mch patogênico obesidade e para determinar a presença ou ausência de receptor de mch em uma amostra, e, uso de um composto
WO2002102778A1 (en)	2001-06-15	2002-12-27	Yamanouchi Pharmaceutical Co., Ltd.	Phenylpyridine carbonyl piperazine derivative
JP4186518B2 (ja) *	2001-06-15	2008-11-26	アステラス製薬株式会社	フェニルピリジン誘導体
EP1452525A4 (en)	2001-10-30	2005-01-26	Nippon Shinyaku Co Ltd	AMIDE DERIVATIVES AND CORRESPONDING MEDICAMENTS
US6620811B2 (en)	2001-11-19	2003-09-16	Hoffmann-La Roche Inc.	Isonicotin- and nicotinamide derivatives of benzothiazoles
CA2468716A1 (en)	2001-11-28	2003-06-05	Fujisawa Pharmaceutical Co., Ltd.	Heterocyclic amide compounds as apolipoprotein b inhibitors
EP1456175A1 (en)	2001-12-07	2004-09-15	Eli Lilly And Company	Substituted heterocyclic carboxamides with antithrombotic activity
CN1628109A (zh)	2002-02-05	2005-06-15	诺沃挪第克公司	新颖的芳基－与杂芳基－哌嗪
EA006707B1 (ru)	2002-03-13	2006-02-24	Янссен Фармацевтика Н. В.	Сульфонилпроизводные в качестве новых ингибиторов гистон-деацетилазы
CN1305850C (zh)	2002-03-13	2007-03-21	詹森药业有限公司	作为组蛋白脱乙酰酶新颖抑制剂的磺酰基氨基衍生物
OA12790A (en)	2002-03-13	2006-07-10	Janssen Pharmaceutica Nv	New inhibitors of histone deacetylase.
MXPA04010555A (es)	2002-04-25	2005-02-17	Pharmacia Corp	Acidos piperidinil- y piperazinil-sulfonilmetil hidroxamicos y su uso como inhibidores de proteasa.
CA2493584A1 (en)	2002-07-25	2004-02-05	Wisconsin Alumni Research Foundation	Inhibition of stearoyl-coa desaturase 1 (scd1) increases insulin sensitivity and treats diabetes
US7582761B2 (en)	2002-10-17	2009-09-01	Amgen Inc.	Vanilloid receptor ligands and their use in treatments
JP2004203871A (ja)	2002-12-13	2004-07-22	Yamanouchi Pharmaceut Co Ltd	医薬組成物
WO2004065378A1 (en)	2003-01-17	2004-08-05	Warner-Lambert Company Llc	2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
TWI345974B (en)	2003-07-30	2011-08-01	Xenon Pharmaceuticals Inc	Pyridazine derivatives and their use in the inhibition of stearoyl-coa desaturase
ES2386353T3 (es)	2003-07-30	2012-08-17	Xenon Pharmaceuticals Inc.	Derivados de piridazina y su uso como agentes terapéuticos
CN101693697A (zh)	2003-07-30	2010-04-14	泽农医药公司	哌嗪衍生物和它们作为治疗剂的用途

2004
- 2004-07-29 TW TW093122736A patent/TWI345974B/zh not_active IP Right Cessation
- 2004-07-29 EP EP10184939.6A patent/EP2316827B1/en not_active Expired - Lifetime
- 2004-07-29 EP EP16000190.5A patent/EP3042895A1/en not_active Withdrawn
- 2004-07-29 US US10/901,563 patent/US7335658B2/en not_active Expired - Fee Related
- 2004-07-29 TW TW099123172A patent/TW201038270A/zh unknown
- 2004-07-29 DK DK04779562.0T patent/DK1648874T3/da active
- 2004-07-29 CA CA2533899A patent/CA2533899C/en not_active Expired - Lifetime
- 2004-07-29 EP EP04779562A patent/EP1648874B1/en not_active Expired - Lifetime
- 2004-07-29 JP JP2006522075A patent/JP4808616B2/ja not_active Expired - Fee Related
- 2004-07-29 PL PL04779562T patent/PL1648874T3/pl unknown
- 2004-07-29 ES ES10184939.6T patent/ES2568769T3/es not_active Expired - Lifetime
- 2004-07-29 HR HR20110974T patent/HRP20110974T1/hr unknown
- 2004-07-29 KR KR1020067002017A patent/KR100934554B1/ko not_active Expired - Fee Related
- 2004-07-29 AT AT04779562T patent/ATE527242T1/de active
- 2004-07-29 ES ES04779562T patent/ES2375134T3/es not_active Expired - Lifetime
- 2004-07-29 WO PCT/US2004/024548 patent/WO2005011655A2/en not_active Ceased
- 2004-07-29 AU AU2004261252A patent/AU2004261252C1/en not_active Ceased
- 2004-07-29 PT PT04779562T patent/PT1648874E/pt unknown
- 2004-07-29 NZ NZ545265A patent/NZ545265A/en not_active IP Right Cessation
- 2004-07-29 AR ARP040102690A patent/AR047557A1/es not_active Application Discontinuation
2006
- 2006-01-25 EC EC2006006313A patent/ECSP066313A/es unknown
- 2006-01-26 IL IL173395A patent/IL173395A/en not_active IP Right Cessation
- 2006-01-27 TN TNP2006000034A patent/TNSN06034A1/en unknown
- 2006-02-27 MA MA28839A patent/MA28011A1/fr unknown
- 2006-02-28 NO NO20060981A patent/NO332822B1/no not_active IP Right Cessation
2009
- 2009-05-05 AU AU2009201788A patent/AU2009201788B2/en not_active Ceased
2011
- 2011-12-29 CY CY20111101290T patent/CY1112178T1/el unknown
2016
- 2016-12-23 HK HK16114675.5A patent/HK1226399A1/en unknown

Also Published As

Publication number	Publication date
AU2004261252C1 (en)	2009-09-17
EP1648874B1 (en)	2011-10-05
JP2007500717A (ja)	2007-01-18
IL173395A0 (en)	2006-06-11
IL173395A (en)	2013-03-24
AU2004261252A1 (en)	2005-02-10
HK1226399A1 (en)	2017-09-29
TWI345974B (en)	2011-08-01
TNSN06034A1 (en)	2007-10-03
US7335658B2 (en)	2008-02-26
KR20060036107A (ko)	2006-04-27
NO20060981L (no)	2006-05-02
ATE527242T1 (de)	2011-10-15
CY1112178T1 (el)	2015-12-09
AU2009201788B2 (en)	2012-04-05
EP1648874A2 (en)	2006-04-26
HK1097256A1 (zh)	2007-06-22
NO332822B1 (no)	2013-01-21
TW201038270A (en)	2010-11-01
PL1648874T3 (pl)	2012-04-30
ES2375134T3 (es)	2012-02-27
TW200518753A (en)	2005-06-16
JP4808616B2 (ja)	2011-11-02
MA28011A1 (fr)	2006-07-03
EP3042895A1 (en)	2016-07-13
CA2533899A1 (en)	2005-02-10
AU2004261252B2 (en)	2009-02-05
ECSP066313A (es)	2006-07-28
EP2316827A1 (en)	2011-05-04
WO2005011655A2 (en)	2005-02-10
ES2568769T3 (es)	2016-05-04
NZ545265A (en)	2009-11-27
CA2533899C (en)	2011-01-04
PT1648874E (pt)	2011-12-23
AR047557A1 (es)	2006-01-25
HRP20110974T1 (hr)	2012-01-31
KR100934554B1 (ko)	2009-12-29
WO2005011655A3 (en)	2005-03-24
EP2316827B1 (en)	2016-01-27
AU2009201788A1 (en)	2009-05-28
US20050065143A1 (en)	2005-03-24

Publication	Publication Date	Title
DK1648874T3 (da)	2012-01-23	Piperazinderivater samt deres anvendelse som terapeutisk aktive stoffer
DK1585749T3 (da)	2008-09-22	Diazepinoindol-derivater som kinaseinhibitorer
NO20032909D0 (no)	2003-06-24	Glukopyranosyloksypyrazolderivater samt medikamentell anvendelse derav
NO20050426L (no)	2005-03-29	Arylkarbonylderivater som terapeutiske midler
EP1587535A4 (en)	2010-02-24	N-cyclohexylaminocarbonyl-benzenesulfonamide derivatives
DE602004029145D1 (de)	2010-10-28	Pyrazolopyridin-derivate
DK1549283T3 (da)	2013-01-02	Merocyanine derivatives for cosmetic use
ATE398112T1 (de)	2008-07-15	Substituierte morpholin- und thiomorpholinderivate
IS7872A (is)	2005-05-30	Pýrrólópýrimidín afleiður
DK1478629T3 (da)	2007-01-29	N-aryl-2-oxazolidinon-5-carboxamider og deres derivater og deres anvendelse som antibakterielle midler
DK1594840T3 (da)	2007-02-05	Piperidin-benzensulfonamid-derivater
CY2017048I1 (el)	2018-09-05	Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης
DK1828167T3 (da)	2014-10-20	Acrylamidderivater som antibiotiske midler
ATE352550T1 (de)	2007-02-15	Chinazolinderivate
DK1682493T3 (da)	2009-04-20	Amidoacetonitrilderivater
DK1578750T3 (da)	2008-03-17	Kationiske porphyrinderivater som antibakterielle midler
ATE395345T1 (de)	2008-05-15	Imidazol-4-yl-ethynyl-pyridin-derivate
IS8180A (is)	2005-12-14	Nýjar besímídasólafleiður
ATE512960T1 (de)	2011-07-15	Pyrimidinderivate
DK1763517T3 (da)	2011-06-06	Pyrimidinderivater som 11beta-HSD1-inhibitorer
DE60335075D1 (de)	2011-01-05	Flüssigkeitszerstäuber
DK2091924T3 (da)	2011-10-03	Pyrimidinderivater samt deres anvendelse som pesticider
NO20044092L (no)	2004-09-27	Oftalmisk sammensetning som innbefatter ascomycin
ATE354365T1 (de)	2007-03-15	N-thiazol-2-yl-benzamid-derivate
DK1624869T3 (da)	2012-10-01	Doseringsform indeholdende pantoprazol som aktiv bestanddel